NEW YORK (GenomeWeb) – Metabolon announced that it is partnering with Geisinger Medical Center in Danville, Pa., on a pilot study to evaluate Metabolon's Quantose IR test in monitoring glycemic control in people with prediabetes.
The study will monitor prediabetic subjects over a 12-week period using the Quantose IR test and evaluate hemoglobin A1c and fasting plasma glucose results. Participants in the study will receive metformin treatment and also will be on a regiment of diet and exercise.
Quantose IR is a laboratory-developed metabolomic test that uses three recently identified non-glycemic biomarkers. According to the Research Triangle Park, NC-based firm, the test can assess risk of progression to diabetes earlier than traditional glycemic measures.
"This study is important because it has the potential to document the effectiveness of Quantose IR as a monitor for prediabetes therapy," Metabolon President and CEO John Ryals said in a statement. "Our goal is to provide physicians with a new tool that can track changes in insulin resistance that may be missed by other glycemic tests such as fasting plasma glucose and hemoglobin A1c."